FDA clears Lilly’s Retevmo for RET-positive lung, thyroid ca...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo.

Lilly keeps ahead of Blueprint with swift FDA review for sel...

Relief for Lilly as drug from $8bn Loxo deal clears pivotal ...